TABLE 1.

Cohort Characteristics

Transplant patients
Age, median (range)	6.2 (4m - 17.9y)
Female sex, n(%)	25 (28.4%)
Race
Asian	2 (2.3%)
Black	8 (9.1%)
White	66 (75.0%)
Multiple	1 (1.1%)
Not reported	11 (12.5%)
Hospital
Children’s Hospital of Philadelphia	42 (47.7%)
Cincinnati Children’s Hospital Medical Center	19 (21.6%)
Nationwide Children’s Hospital	10 (11.4%)
Children’s Hospital of Pittsburgh	17 (19.3%)
Indication for transplant
Malignancy	35 (39.8%)
Immunodeficiency/Immunedysregulation	33 (37.5%)
Bone marrow failure	10 (11.4%)
Other	10 (11.4%)
Conditioning intensity
Myeloablative	56 (67.5%)
Non-myeloablative/Reduced intensity	27 (32.5%)
Receipt of serotherapy	60 (68.2%)
Anti-thymocyte globulin	38 (43.2%)
Alemtuzumab	22 (25.0%)
Healthy controls
Age, median (range)	5.6y (4m - 17.6y)
Female sex, n(%)	27 (51.9%)